Tel.: +33 (0)9 72 56 94 99


We believe that facing the challenge of safe and fast drug development, for the benefit of patients, is no longer a challenge that any pharmaceutical or biotech company can face on its own. Building effective collaborations of all kinds – from early stage development until clinical trials – is a priority for Inoviem Scientific.

Inoviem Scientific provides its cutting-edge, label-free technologies and its expertise to any pharmaceutical or biotech company involved in a challenging drug development program.

Through collaboration agreements, Inoviem Scientific will use its technologies to:

  • identify your drug target (therapeutic and toxic) in any human tissue (healthy or pathologic)
  • clarify its mechanism of action
  • identify and validate functional associated biomarkers
  • identify responder patients in your phase 0 or phase 2 clinical trials in order to optimise the outcome of your clinical trial.

You will benefit from an experienced team, a project-oriented program and cutting-edge, label-free technologies unique on the market which get rid of labels bias.

Inoviem Scientific has been involved in challenging projects to unlock drug development programs.

Please see references.

Whether you want to know more about Inoviem Scientific technologies or if you have a partnering request to work with our seasoned team, please contact:

Dr Daniel Da Costa

Dr Daniel Da Costa
Communication and Commercial Officer (CCO)
+33 (0)9 72 56 95 02